- Home
- ANVS vs MAIA Comparison
ANVS vs MAIA Comparison
Compare ANVS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- MAIA
- Stock Information
- Founded
- ANVS 2008
- MAIA 2018
- Country
- ANVS United States
- MAIA United States
- Employees
- ANVS N/A
- MAIA N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- MAIA Health Care
- Exchange
- ANVS Nasdaq
- MAIA Nasdaq
- Market Cap
- ANVS 46.1M
- MAIA 56.7M
- IPO Year
- ANVS 2020
- MAIA 2022
- Fundamental
- Price
- ANVS $2.21
- MAIA $1.36
- Analyst Decision
- ANVS Strong Buy
- MAIA
- Analyst Count
- ANVS 4
- MAIA 0
- Target Price
- ANVS $17.33
- MAIA N/A
- AVG Volume (30 Days)
- ANVS 1.3M
- MAIA 598.3K
- Earning Date
- ANVS 11-07-2025
- MAIA 11-11-2025
- Dividend Yield
- ANVS N/A
- MAIA N/A
- EPS Growth
- ANVS N/A
- MAIA N/A
- EPS
- ANVS N/A
- MAIA N/A
- Revenue
- ANVS N/A
- MAIA N/A
- Revenue This Year
- ANVS N/A
- MAIA N/A
- Revenue Next Year
- ANVS N/A
- MAIA N/A
- P/E Ratio
- ANVS N/A
- MAIA N/A
- Revenue Growth
- ANVS N/A
- MAIA N/A
- 52 Week Low
- ANVS $1.11
- MAIA $1.26
- 52 Week High
- ANVS $10.54
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- ANVS 51.88
- MAIA 38.45
- Support Level
- ANVS $1.90
- MAIA $1.26
- Resistance Level
- ANVS $2.21
- MAIA $1.97
- Average True Range (ATR)
- ANVS 0.18
- MAIA 0.12
- MACD
- ANVS 0.02
- MAIA -0.04
- Stochastic Oscillator
- ANVS 56.23
- MAIA 12.65
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.